Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...
Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Four ...
Is AnaptysBio, Inc. (ANAB) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...
On Wednesday, AnaptysBio Inc (ANAB) stock saw a decline, ending the day at $16.18 which represents a decrease of $-0.70 or -4.15% from the prior close of $16.88. The stock opened at $16.83 and touched ...
Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback